M
Marta Radaelli
Researcher at Vita-Salute San Raffaele University
Publications - 84
Citations - 2174
Marta Radaelli is an academic researcher from Vita-Salute San Raffaele University. The author has contributed to research in topics: Multiple sclerosis & Medicine. The author has an hindex of 21, co-authored 70 publications receiving 1432 citations.
Papers
More filters
Journal ArticleDOI
Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis.
Maria Pia Sormani,Nicola De Rossi,Irene Schiavetti,Luca Carmisciano,Cinzia Cordioli,Lucia Moiola,Marta Radaelli,Paolo Immovilli,Marco Capobianco,Maria Trojano,Paola Zaratin,Gioacchino Tedeschi,Giancarlo Comi,Mario Alberto Battaglia,Mario Alberto Battaglia,Francesco Patti,Marco Salvetti +16 more
TL;DR: In this paper, the impact of immunosuppressive and immunomodulatory therapies on the severity of coronavirus disease 2019 (COVID-19) in people with multiple sclerosis (PwMS) was evaluated by multivariate and propensity score (PS)-weighted ordinal logistic models.
Journal ArticleDOI
Evolving concepts in the treatment of relapsing multiple sclerosis.
TL;DR: Before starting a treatment, neurologists should carefully consider the state of the disease, its prognostic factors and comorbidities, the patient's response to previous treatments, and whether the patient is likely to accept treatment-related risks in order to maximise benefits and minimise risks.
Journal ArticleDOI
Functional network connectivity abnormalities in multiple sclerosis: Correlations with disability and cognitive impairment.
Maria A. Rocca,Paola Valsasina,Victoria M. Leavitt,Mariaemma Rodegher,Marta Radaelli,Gianna C Riccitelli,Vittorio Martinelli,Filippo Martinelli-Boneschi,Andrea Falini,Giancarlo Comi,Massimo Filippi +10 more
TL;DR: Investigating resting state (RS) functional connectivity abnormalities within the principal brain networks in a large cohort of multiple sclerosis patients found a complex pattern of decreased and increased RS FC, which contributes to a wide spectrum of clinical manifestations.
Journal ArticleDOI
A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis.
Maira Gironi,Filippo Martinelli-Boneschi,Paola Sacerdote,Claudio Solaro,Mauro Zaffaroni,Rosella Cavarretta,Lucia Moiola,S. Bucello,Marta Radaelli,V. Pilato,Mariaemma Rodegher,Marco Cursi,Silvia Franchi,Vittorio Martinelli,Raffaello Nemni,Giancarlo Comi,Gianvito Martino +16 more
TL;DR: The data clearly indicate that LDN is safe and well tolerated in patients with PPMS and a significant reduction of spasticity was measured at the end of the trial.
Journal ArticleDOI
Mitoxantrone: benefits and risks in multiple sclerosis patients
TL;DR: The most serious risks of the MTX drug are represented by potential cardiotoxicity and leukaemia, whose incidence seems to be higher than previously reported.